New Comprehensive Clinical Classification of the Dry Eye Syndrome Severity 2024. Part 2. Treatment Algorithm — the Opinion of Ophthalmologists

The first part of the article presented the developed clinical classification of the severity of dry eye syndrome 2024, which takes into account not only objective indicators of the state of tear production and the degree of inflammation of the tissues of the ocular surface, but also subjective indicators — patient complaints (SPEED quality of life scale). This classification allows to determine the severity of dry eye syndrome (DES), which in turn makes it possible to choose an adequate volume and type of therapy for this disease. The study presented in this article, conducted on the basis of a questionnaire of ophthalmologist experts (Delphi method), made it possible to formulate an algorithm for treating dry eye syndrome using the developed comprehensive clinical classification of the severity of this pathology. The ophthalmologist expert determined the indications for prescribing various groups of drugs — tear substitutes, corneoprotectors: gels containing dexpanthenol, ointment forms. Anti-inflammatory therapy — dexamethasone, antiallergic, nonsteroidal anti-inflammatory drugs, blood products (autologous/alogeneic serum, PRP), cyclosporine, antiseptics. Physiotherapeutic treatment — eyelid hygiene: warm compresses/irrigation of the eyelid surface with warm water + eyelid self-massage, IPL therapy, Aktiva system, Plasma jett system. The algorithm allows to determine indications for 13 types of dry eye syndrome therapy recommended for use by the international working group The Tear Film & Ocular Surface depending on the severity of dry eye syndrome (mild, moderate, severe), the presence of concomitant pathology or taking medications on an ongoing basis, as well as the duration of dry eye syndrome. Given the high level of expert agreement in the assessment (Randolph kappa coefficient above 0.6) when compiling the algorithm, it can be recommended for use in a wide ophthalmological practice, including primary outpatient care.

1. Трубилин АВ, Трубилин ВН, Полунина ЕГ, Каспарова ЕА. Новая комплексная клиническая классификация степени тяжести синдрома сухого глаза 2024. Часть 1. Офтальмология. 2024;21(4):709–715.

2. Troisi M, Del Prete S, Troisi S, Marasco D, Rinaldi M, Costagliola C. Scanning Electron Microscopy (SEM) Evaluation of the Ultrastructural Effects on Conjunctival Epithelial Cells of a New Multiple-Action Artificial Tear Containing Cross-Linked Hyaluronic Acid, Cationic Liposomes and Trehalose. Biomedicines. 2024 Aug 23;12(9):1945. doi: 10.3390/biomedicines12091945.

3. Schrage NF, Frentz M, Reim M. Changing the composition of buffered eye-drops prevents undesired side effects. Br J Ophthalmol. 2010 Nov;94(11):1519–1522. doi: 10.1136/bjo.2009.177386.

4. Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, Utheim TP, Rolando M. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801.

5. Rajendraprasad RM, Kwatra G, Batra N. Carboxymethyl Cellulose versus Hydroxypropyl Methylcellulose Tear Substitutes for Dry Eye Due to Computer Vision Syndrome: Comparison of Efficacy and Safety. Int J Appl Basic Med Res. 2021 Jan-Mar;11(1):4–8. doi: 10.4103/ijabmr.IJABMR_399_20.

6. Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022 Oct;42(10):3253–3272. doi: 10.1007/s10792-022-02320-7.

7. Ahn H, Kim BY, Kim J, Ji YW, Jun I, Kim TI, Lee HK, Seo KY. How Long to Continue Eyelid Hygiene to Treat Meibomian Gland Dysfunction. J Clin Med. 2022 Jan 20;11(3):529. doi: 10.3390/jcm11030529.

8. Tanabe H, Kaido M, Kawashima M, Ishida R, Ayaki M, Tsubota K. Effect of Eyelid Hygiene Detergent on Obstructive Meibomian Gland Dysfunction. J Oleo Sci. 2019 Jan 1;68(1):67–78. doi: 10.5650/jos.ess18161.

9. Bitton E, Ngo W, Dupont P. Eyelid hygiene products: A scoping review. Cont Lens Anterior Eye. 2019 Dec;42(6):591–597. doi: 10.1016/j.clae.2019.09.008.

10. Медведев ИБ, Трубилин ВН, Полунина ЕГ, Дергачева НН, Анджелова ДВ, Евстигнеева ЮВ. Современные возможности физиотерапевтического лечения дисфункции мейбомиевых желез. Офтальмология. 2022;19(2):235–241.

11. Трубилин АВ, Полунина ЕГ, Трубилин ВН, Закатянский ВС. Профилактика синдрома сухого глаза перед проведением факоэмульсификации катаракты у пациентов с косметологическими процедурами в периорбитальной зоне в анамнезе. Офтальмология. 2024;21(3):517–526.

12. Gade A, Vasile GF, Hohman MH, Rubenstein R. Intense Pulsed Light (IPL) Therapy. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 35593833.

13. Майчук ДЮ, Лошкарева АО, Цветкова ТВ. Алгоритм комплексной терапии синдрома сухого глаза с дисфункцией мейбомиевых желез интенсивным импульсным светом (IPL) в сочетании с гигиеной век и слезозамещением. Офтальмология. 2020;17(3s):640–647.

14. Li S, Yang K, Wang J, Li S, Zhu L, Feng J, Tian L, Jie Y. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. Ophthalmol Ther. 2022 Feb;11(1):261–270. doi: 10.1007/s40123021‑00431‑5.

15. Shin KY, Lim DH, Moon CH, Kim BJ, Chung TY. Intense pulsed light plus meibomian gland expression versus intense pulsed light alone for meibomian glanddysfunction: A randomized crossover study. PLoS One. 2021 Mar 4;16(3):e0246245. doi: 10.1371/journal.pone.0246245.

16. Cote S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559.

17. Vigo L, Pellegrini M, Carones F, Scorcia V, Giannaccare G. Short-Term Effects of a Novel Eye Mask Producing Heat and Vibration for the Treatment of Meibomian Gland Dysfunction: A Pilot Study. J Ophthalmol. 2021 Aug 17;2021:1370002. doi: 10.1155/2021/1370002.

18. Vigo L, Pellegrini M, Carones F, Scorcia V, Giannaccare G. Outcomes of serial sessions of Activa mask combined with intense pulsed light therapy in patients with Meibomian gland dysfunction. BMC Ophthalmol. 2022 Jul 19;22(1):313. doi: 10.1186/s12886-022-02538-0.

19. Fait T, Baltazár T, Bubenickova L, Kestranek J, Stepan M, Muller M, Turcan P. Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study. J Clin Med. 2023 Sep 27;12(19):6234. doi: 10.3390/jcm12196234.

20. Zemanova M. Treatment of mild forms of blepharitis using direct plasma discharge Advances in Ophthalmology & Visual System Preliminary Report. Advances in Ophthalmology & Visual System. 2020; 10:127–130. doi: 10.15406/aovs.2020.10.00397.

21. Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, O’Reilly NJ, O’Donovan O, McLoughlin P, Fitzhenry L. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease. Pharmaceutics. 2021 Jun 18;13(6):905. doi: 10.3390/pharmaceutics13060905.

22. Lin MX, Guo L, Saldanha IJ, VanCourt S, Zeng J, Karakus S, Hessen M, Li G, Akpek EK. Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye: A Randomized Controlled Trial. Ophthalmology. 2024 Sep;131(9):1033–1044. doi: 10.1016/j.ophtha.2024.03.010.

23. Li X, Jin X, Wang J, Li X, Zhang H. Dexamethasone attenuates dry eye-induced pyroptosis by regulating the KCNQ1OT1/miR-214 cascade. Steroids. 2022 Oct;186:109073. doi: 10.1016/j.steroids.2022.109073.

24. Utheim TP, Chen X, Fineide F, Steinkjer T, Heegaard S, Kolko M, Dartt DA, Khan AZ. Response predictors of a topical corticosteroid-based regimen for dry eyes: A real-life study. Acta Ophthalmol. 2025 Feb;103(1):93–98. doi: 10.1111/aos.16758.

25. Nguyen A, Kolluru A, Beglarian T. Dry eye disease: A review of anti-inflammatory therapies. Taiwan J Ophthalmol. 2023 Feb 13;13(1):3–12. doi: 10.4103/2211-5056.369606.

26. Messmer EM. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022 Apr;217:108944. doi: 10.1016/j.exer.2022.108944.

27. Vazirani J, Sridhar U, Gokhale N, Doddigarla VR, Sharma S, Basu S. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines. Indian J Ophthalmol. 2023 Apr;71(4):1357–1363. doi: 10.4103/IJO.IJO_2756_22. PMID: 37026267; PMCID: PMC10276663.

28. Kasparova EA, Krivolapova DA. Blood Serum in the Treatment of Epitheliopathy of Various Genesis. Clinical Observations. Ophthalmology in Russia. 2024;21(4):769–776 (In Russ.). doi: 10.18008/1816-5095-2024-4-769-776.

29. Sharkawy HE, Kantarci A, Deady J. Platelet — rich plasma: growth factors and proand anti -inflammatory properties. J. Periodontol. 2007;78(4):661–669. doi: 10.5272/jimab.2016224.1379.

30. Kang MJ, Lee JH, Hwang J, Chung SH. Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren’s syndrome: a randomized trial. Sci Rep. 2023 Nov 7;13(1):19279. doi: 10.1038/s41598-023-46671-2.

31. Jongkhajornpong P, Lekhanont K, Rattanasiri S, Numthavaj P, McKay G, Attia J, Thakkinstian A. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024 Oct 8;9(1):e001857. doi: 10.1136/bmjophth-2024-001857.

32. Jongkhajornpong P, Lekhanont K, Rattanasiri S, Numthavaj P, McKay G, Attia J, Thakkinstian A. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024 Oct 8;9(1):e001857. doi: 10.1136/bmjophth-2024-001857.

33. Balal S, Udoh A, Pappas Y, Cook E, Barton G, Hassan A, Hayden K, Bourne RRA, Ahmad S, Pardhan S, Harrison M, Sharma B, Wasil M, Sharma A. The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. BMJ Open. 2018 Oct 31;8(10):e026770. doi: 10.1136/bmjopen-2018-026770.

34. Gao M, Zhao L, Liang R, Zhu Q, Zhao Q, Kong X. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren’s Syndrome. Ocul Immunol Inflamm. 2023 Oct;31(8):1662–1668. doi: 10.1080/09273948.2022.2094812.

35. Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol. 2022 Jan;32(1):673–679. doi: 10.1177/1120672121992680.

36. Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, Hoshino-Ruiz DR, Albers MB, Santo RM, Hida RY. Treatment of Sjögren’s syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study. Cont Lens Anterior Eye. 2015 Oct;38(5):373–378. doi: 10.1016/j.clae.2015.04.004.

37. Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother. 2013 Aug;14(11):1449–1465. doi: 10.1517/14656566.2013.802773.

38. Trubilin VN, Poluninа EG, Kozhukhov AA, Kurenkov VV, Moreva NV, Trubilin AV. Medical therapy for conjunctivitis. Literature review. The EYE GLAZ. 2023;25(3):225–233 (In Russ.). doi: 10.33791/2222-4408-2023-3-225-233.

39. Craig JP, Alves M, Wolffsohn JS, Downie LE, Efron N, Galor A, Gomes JAP, Jones L, Markoulli M, Stapleton F, Starr CE, Sullivan AG, Willcox MDP, Sullivan DA. TFOS Lifestyle Report Introduction: A Lifestyle Epidemic — Ocular Surface Disease. Ocul Surf. 2023 Apr;28:304–309. doi: 10.1016/j.jtos.2023.04.014. Epub 2023 Apr 29. PMID: 37121544.